The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new ...

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about how technological advances will impact the ...

The API is, one might say, the most important element in a pharmaceutical product. Poor-quality APIs that do not meet potency ...

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations ...

Scientific, economic, and practical factors should be considered when choosing between the frozen state and lyophilization.

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about how geopolitical instability in Europe, and ...

BioPharm International® sat down with Noah Kopcho, field application scientist at Gyros Protein Technologies, to talk about ...

Building relationships with customers who are as focused you are on innovation for a better world is a perfect starting point and premise for a successful project. Merck & Co. Inc., a global health ...